Abstract
In order to study the relationship between circulating levels of CA 15-3 and the disease extent in predicting survival, we prospectively followed 312 breast cancer (BC) patients, from October 1988 to March 1995, from the time of first relapse. CA 15-3 values were assessed before treatment onset. Disease extent was defined as the percentage of liver or lung involvement and the number of bone segments positive at scintigraphy. The covariates were primary tumour characteristics (T, N and hormone receptor status) and patient characteristics at recurrence (menopause, performance status and age). Higher CA 15-3 serum levels were found in patients with visceral metastases or with pleural effusion. A logistic regression model selected disease extent in liver, lung and bone as independent variables for the determination of abnormal CA 15-3 values. Univariate survival analysis confirmed the positive prognostic influence of low CA 15-3 serum levels, absence of visceral metastases and the presence of only one metastatic site. Multivariate Cox's survival analysis selected disease extent in liver, lung, bone and soft tissue but not level of CA 15-3 as prognostic factors. In conclusion, CA 15-3 is not an independent variable in determining survival, its prognostic role being linked to the disease extent. This association suggests that CA 15-3 may be useful in assessing disease extent when this is not easily assessable.
Full text
PDF




Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Berruti A., Tampellini M., Torta M., Buniva T., Gorzegno G., Dogliotti L. Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of disease. Eur J Cancer. 1994;30A(14):2082–2084. doi: 10.1016/0959-8049(94)00356-a. [DOI] [PubMed] [Google Scholar]
- Bombardieri E., Pizzichetta M., Veronesi P., Seregni E., Bogni A., Maffioli L., Jotti G. S., Bassetto M. A., Zurrida S., Costa A. CA 15.3 determination in patients with breast cancer: clinical utility for the detection of distant metastases. Eur J Cancer. 1992;29A(1):144–146. doi: 10.1016/0959-8049(93)90595-7. [DOI] [PubMed] [Google Scholar]
- Chlebowski R. T., Lillington L. M. A decade of breast cancer clinical investigation: results as reported in the Program/Proceedings of the American Society of Clinical Oncology. J Clin Oncol. 1994 Sep;12(9):1789–1795. doi: 10.1200/JCO.1994.12.9.1789. [DOI] [PubMed] [Google Scholar]
- Clark G. M., Sledge G. W., Jr, Osborne C. K., McGuire W. L. Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol. 1987 Jan;5(1):55–61. doi: 10.1200/JCO.1987.5.1.55. [DOI] [PubMed] [Google Scholar]
- Clavel M., Catimel G. Breast cancer: chemotherapy in the treatment of advanced disease. Eur J Cancer. 1993;29A(4):598–604. doi: 10.1016/s0959-8049(05)80161-3. [DOI] [PubMed] [Google Scholar]
- Colomer R., Ruibal A., Salvador L. Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. Cancer. 1989 Oct 15;64(8):1674–1681. doi: 10.1002/1097-0142(19891015)64:8<1674::aid-cncr2820640820>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
- Dogliotti L., Berruti A., Buniva T., Zola P., Baù M. G., Farris A., Sarobba M. G., Bottini A., Alquati P., Deltetto F. Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial. J Clin Oncol. 1996 Apr;14(4):1165–1172. doi: 10.1200/JCO.1996.14.4.1165. [DOI] [PubMed] [Google Scholar]
- Geraghty J. G., Coveney E. C., Sherry F., O'Higgins N. J., Duffy M. J. CA 15-3 in patients with locoregional and metastatic breast carcinoma. Cancer. 1992 Dec 15;70(12):2831–2834. doi: 10.1002/1097-0142(19921215)70:12<2831::aid-cncr2820701218>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
- Gion M., Cappelli G., Mione R., Pistorello M., Meo S., Vignati G., Fortunato A., Saracchini S., Biasioli R., Giulisano M. Evaluation of critical differences of CEA and CA 15.3 levels in serial samples from patients operated for breast cancer. Int J Biol Markers. 1994 Jul-Sep;9(3):135–139. doi: 10.1177/172460089400900302. [DOI] [PubMed] [Google Scholar]
- Gourevitch M. M., von Mensdorff-Pouilly S., Litvinov S. V., Kenemans P., van Kamp G. J., Verstraeten A. A., Hilgers J. Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients. Br J Cancer. 1995 Oct;72(4):934–938. doi: 10.1038/bjc.1995.436. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gregory W. M., Smith P., Richards M. A., Twelves C. J., Knight R. K., Rubens R. D. Chemotherapy of advanced breast cancer: outcome and prognostic factors. Br J Cancer. 1993 Nov;68(5):988–995. doi: 10.1038/bjc.1993.467. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hayes D. F., Henderson I. C., Shapiro C. L. Treatment of metastatic breast cancer: present and future prospects. Semin Oncol. 1995 Apr;22(2 Suppl 5):5–21. [PubMed] [Google Scholar]
- Hayes D. F. Tumor markers for breast cancer. Ann Oncol. 1993 Dec;4(10):807–819. doi: 10.1093/oxfordjournals.annonc.a058385. [DOI] [PubMed] [Google Scholar]
- Henson D. E., Ries L., Freedman L. S., Carriaga M. Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. The basis for a prognostic index. Cancer. 1991 Nov 15;68(10):2142–2149. doi: 10.1002/1097-0142(19911115)68:10<2142::aid-cncr2820681010>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
- Jotti G. S., Bombardieri E. Circulating tumor markers in breast cancer (review). Anticancer Res. 1990 Jan-Feb;10(1):253–258. [PubMed] [Google Scholar]
- Koenders P. G., Beex L. V., Kloppenborg P. W., Smals A. G., Benraad T. J. Human breast cancer: survival from first metastasis. Breast Cancer Study Group. Breast Cancer Res Treat. 1992;21(3):173–180. doi: 10.1007/BF01975000. [DOI] [PubMed] [Google Scholar]
- La Vecchia C., Negri E., Decarli A., Fasoli M., Cislaghi C. Cancer mortality in Italy: an overview of age-specific and age-standardised trends from 1955 to 1984. Tumori. 1990 Apr 30;76(2):87–166. doi: 10.1177/030089169007600202. [DOI] [PubMed] [Google Scholar]
- Robertson J. F., Pearson D., Price M. R., Selby C., Blamey R. W., Howell A. Objective measurement of therapeutic response in breast cancer using tumour markers. Br J Cancer. 1991 Oct;64(4):757–763. doi: 10.1038/bjc.1991.394. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Safi F., Kohler I., Röttinger E., Suhr P., Beger H. G. Comparison of CA 15-3 and CEA in diagnosis and monitoring of breast cancer. Int J Biol Markers. 1989 Oct-Dec;4(4):207–214. doi: 10.1177/172460088900400405. [DOI] [PubMed] [Google Scholar]
- Swenerton K. D., Legha S. S., Smith T., Hortobagyi G. N., Gehan E. A., Yap H. Y., Gutterman J. U., Blumenschein G. R. Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res. 1979 May;39(5):1552–1562. [PubMed] [Google Scholar]
- Sölétormos G., Nielsen D., Schiøler V., Skovsgaard T., Winkel P., Mouridsen H. T., Dombernowsky P. A novel method for monitoring high-risk breast cancer with tumor markers: CA 15.3 compared to CEA and TPA. Ann Oncol. 1993 Dec;4(10):861–869. doi: 10.1093/oxfordjournals.annonc.a058394. [DOI] [PubMed] [Google Scholar]
- Tondini C., Hayes D. F., Gelman R., Henderson I. C., Kufe D. W. Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res. 1988 Jul 15;48(14):4107–4112. [PubMed] [Google Scholar]
- Yadav G. C., Rao A., Motawy M. M., Safadi N., Ahmed M. J. CA 15.3 with urinary calcium excretion is useful in the diagnosis and monitoring of bone metastases from breast cancer. Int J Biol Markers. 1993 Oct-Dec;8(4):208–214. doi: 10.1177/172460089300800402. [DOI] [PubMed] [Google Scholar]
- Zinser J. W., Hortobagyi G. N., Buzdar A. U., Smith T. L., Fraschini G. Clinical course of breast cancer patients with liver metastases. J Clin Oncol. 1987 May;5(5):773–782. doi: 10.1200/JCO.1987.5.5.773. [DOI] [PubMed] [Google Scholar]
- de Wit R., Hoek F. J., Bakker P. J., Veenhof C. H. A comparison of CA-549 with CA 15-3 and MCA in patients with metastatic breast cancer. Ann Oncol. 1992 Apr;3(4):314–315. doi: 10.1093/oxfordjournals.annonc.a058190. [DOI] [PubMed] [Google Scholar]